CRDF Q4 2024 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$151,000-3.2% YoY

Gross Profit

$151,000100.0% margin

Operating Income

-$13M-8325.8% margin

Net Income

-$12M-7806.0% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-8.5%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$97M

Total Liabilities

$14M

Stockholders' Equity

$83M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$151,000	$156,000	-3.2%
Gross Profit	$151,000	$53,000	+184.9%
Operating Income	-$13M	-$10M	-21.7%
Net Income	-$12M	-$9M	-26.2%